Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
abetimus sodium (LJP 394)
DRUG
3 trials
Sponsors
La Jolla Pharmaceutical Company
Conditions
Autoimmune Diseases
Immunologic Diseases
Lupus Erythematosus, Systemic
Lupus Glomerulonephritis
Lupus Nephritis
Systemic Lupus Erythematosus
Phase 2
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
Withdrawn
NCT00390091
La Jolla Pharmaceutical Company
Systemic Lupus Erythematosus
Start: 2006-09-30
Updated: 2015-09-01
Phase 3
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
Completed
NCT00035308
La Jolla Pharmaceutical Company
Autoimmune Diseases, Immunologic Diseases, Lupus Glomerulonephritis +2
End: 2002-12-31
Target: 330
Updated: 2006-09-25
Study of LJP 394 in Lupus Patients With History of Renal Disease
Terminated
NCT00089804
La Jolla Pharmaceutical Company
Lupus Erythematosus, Systemic, Lupus Nephritis
Start: 2004-10-31
End: 2009-02-28
Updated: 2009-04-01